TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

126 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

115 studies on the map

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease — Research Site, BirminghamStatin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study — Stanford University, StanfordAutologous Stem Cell Transplant for Crohn's Disease — Icahn School of Medicine at Mount Sinai, New YorkA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaStudy of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis — GI Alliance, Sun CitySub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults — Harbor UCLA Medical Center, TorranceAn Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis — Erick H. Alayo Medical Corporation - Gastro SB Clinic, Chula VistaA Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) — Woodholme Gastroenterology Associates, Glen BurnieTo Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment — DM Clinical Research - Phoenix, PhoenixEffect of Statins on Crohn's Disease — Stanford University, StanfordAutologous Stem Cell Transplantation for Crohn's Disease — UPMC Prebyterian- Adult Gastroenterology, PittsburghArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaLY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis — Valleywise Health Medical Center, PhoenixAn Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab — National Institutes of Health Clinical Center, BethesdaStudy of DISC-0974-201 in Participants With IBD and Anemia — One of a Kind Clinical Research Center, LLC, ScottsdaleSelenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies — Northwestern University, ChicagoA Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis — Investigational Site Number: 8400009, EscondidoA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease — Mayo Clinic in Arizona - Scottsdale, ScottsdaleAmitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease — University of Michigan, Ann ArborTreatment of Moderate to Severe Refractory Crohn's Disease — Mayo Clinic Arizona, ScottsdaleA Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) — Clinnova Research ( Site 1042), AnaheimRH Genotype Matched RBC Transfusions — Children's Hospital of Philadelphia, PhiladelphiaBreathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH — Rocky Mountain Regional VA Medical Center, Aurora, CO, AuroraTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesTreatment of UC With Novel Therapeutics — Brigham and Women's Hospital, Chestnut HillStudy of Novel Therapeutics for Acute Remedy of Colitis — Brigham and Women's Hospital, Chestnut HillAquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation — University of Michigan, Ann ArborEfficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease — IMC Gulf Coast Gastroenterology, PC, FairhopeA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — United Medical Doctors, MurrietaCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanRademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) — University of Alabama at Birmingham Lung Health Center, BirminghamA Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP) — Equity Medical Bowling Green, Bowling GreenA Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease — Investigational Site Number: 8400024, TucsonEarly Screening and Treatment of Heart Complication in Sickle Cell Disease — Inova Schar Cancer, FairfaxZinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial — UCSF Benioff Children's Hospital Oakland, OaklandGene Editing For Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisA Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis — Arkansas Children's (IP Address), Little RockAllo HSCT for High Risk Hemoglobinopathies — Masonic Cancer Center, MinneapolisMoving Beyond Inflammation as a Therapeutic Target for Crohn's Disease — Cedars-Sinai Medical Center, Beverly HillsA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) — Gastro Care Institute, LancasterA Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis — Site 024, Canoga ParkA Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD — SEC Clinical Research, LLC, DothanA Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease — Gastro Care Institute, LancasterR-3750 in Patients With Mild to Moderate Ulcerative Colitis — Amicis Research Center, ValenciaA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease — University of Alabama at Birmingham Lung Health Center, BirminghamA Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease — University of Alabama at Birmingham, BirminghamA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) — Memorial Sloan Kettering at Basking Ridge (Consent only), Basking RidgeFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamHB-adMSCs for the Treatment of Crohn's Disease — Hope Biosciences Research Foundation, Sugar LandA Study to Evaluate Solrikitug in Participants With COPD (ZION) — University of Alabama at Birmingham Hospital, BirminghamDetermination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling — National Institutes of Health Clinical Center, BethesdaPartial Stem Cell Transplant for Sickle Cell Disease From Matched Donors — National Institutes of Health Clinical Center, BethesdaStudy to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaHematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies — Boston Children's Hospital, BostonTargeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin — University of Illinois Chicago, Sickle Cell Center, ChicagoBeta-Hydroxybutyrate Feasibility Treating IBD — University of Texas at Austin, AustinStudy of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis — Xencor Investigative Site, ScottsdaleSickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody — Children's National Hospital, Washington D.C.Patient Preference for Subcutaneous vs. Intravenous Immune Therapy — UPMC Hillman Cancer Center, Pittsburgh68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease — Mayo Clinic, RochesterA Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease — Mirador Therapeutics Selected Site, BirminghamSCD Stem Cell Mobilization and Apheresis Using Motixafortide — University of Alabama at Birmingham, BirminghamA Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) — WB Contracted Clinical Research Site, Miami LakesA Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease — Mayo Clinic in Arizona - Scottsdale, ScottsdaleLY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: — Mayo Clinic in Arizona - Scottsdale, ScottsdaleA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — AZ Gastro Care, ChandlerStudy of Panobinostat (LBH589) in Patients With Sickle Cell Disease — Augusta University, AugustaA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — University of Alabama Birmingham, BirminghamStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease — Digestive Health Specialists /ID# 266216, DothanReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders — Yale School of Medicine, New HavenA Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis — AZ Gastro Care - Chandler, ChandlerAlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion — New York Medical College, ValhallaLow Dose IL-2 for the Treatment of Crohn's Disease — Boston Children's Hospital, BostonStandardized Microbiota Transplant Therapy in Crohn's Disease — University of Minnesota, MinneapolisIntravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease — Children's National Hospital, Washington D.C.A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis — One of a Kind Clinical Research Center, ScottsdaleA Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. — GI Alliance - Arizona Digestive Health - Sun City- Site Number : 8400020, Sun CitySafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) — UAMS Medical Center, Little RockThe Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome) — UCSD Sleep Research, La JollaSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis — Univ. of California, San Francisco Health Care, OaklandMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisBiomarker-based Trial of NPC-1 for Alzheimer's Pathology — Massachusetts General Hospital, BostonRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease — Children's Hospital of Colorado, AuroraStudy to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis — The University of Texas Health Science Center at Houston, HoustonAlendronate for Osteonecrosis in Adults With Sickle Cell Disease — UC Davis Comprehensive Cancer Center, SacramentoMyeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease — University of California Los Angeles, Los Angeles: Vascular Function in Health and Disease — George E Wahlen VA Medical Center, Salt Lake CityStudy of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease — University of Illinois at Chicago, ChicagoHaploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease — City of Hope Medical Center, DuarteHyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy — University of Virginia Health System, CharlottesvilleRelationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET — St. Jude Children's Research Hospital, MemphisLung and Bone Marrow Transplantation for Lung and Bone Marrow Failure — UPMC Presbyterian, PittsburghMinimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease — Children's National Health System, Washington D.C.T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias — Children's Hospital of Pittsburgh of UPMC, PittsburghTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — University of Alabama at Birmingham Cancer Center, BirminghamPilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy — Connecticut Children's Medical Center, HartfordA Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease — University of Illinois at Chicago College of Medicine, ChicagoTocilizumab for Acute Chest Syndrome — University of Chicago, ChicagoStem Cell Transplantation in Crohn's Disease — Cedars-Sinai Medical Center, Los AngelesEvaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis — The University of Texas Health Science Center at Houston, HoustonHyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease — University of Kansas Medical Center, Kansas CityPulmonary Hypertension SOLAR — Duke University Medical Center, DurhamGene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesPET Imaging of Vaso-Occlusive Crisis (VOC) in SCD — UPMC, PittsburghThe Use of Butyrate Therapy in Pediatric Ulcerative Colitis — Children's Hospital Los Angeles, Los AngelesEffect of Ensifentrine on Sputum Markers of Inflammation in COPD — University of Alabama at Birmingham, BirminghamCognitive Remediation Intervention to Prepare for Transition of Care — University of Alabama at Birmingham, BirminghamA Phase 2/3 Study in Adult and Adolescent Participants With SCD — Smilow Cancer Hospital, New HavenCannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain — Mount Sinai Hospital, New YorkPrecise Infliximab Exposure and Pharmacodynamic Control — Children's Hospital of Los Angeles, Los AngelesDB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease — Direct Biologics Investigational Site, AuroraInhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia — Duke Asthma Allergy and Airway Center, DurhamClinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD — University of Alabama, Birmingham